AKBAAkebia Ther
About Akebia Ther
Akebia Therapeutics (NASDAQ:AKBA) operates in the biopharmaceutical sector, focusing on the development and commercialization of therapeutics based on harnessing the potential of hypoxia-inducible factor (HIF) for patients with kidney disease and other metabolic disorders. Their primary project is the development of vadadustat, an oral therapy designed to treat anemia due to chronic kidney disease. Akebia's objectives revolve around addressing the unmet medical needs within the kidney disease community by providing innovative treatments aimed at improving patients' quality of life and clinical outcomes. The company is dedicated to advancing its project pipeline through rigorous research and development, aspiring to lead in the nephrology space by offering novel therapeutic solutions.
What is AKBA known for?
Snapshot
Public US
Ownership
2007
Year founded
167
Employees
Cambridge, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Newton, US
Produtos e/ou serviços de Akebia Ther
- Vadadustat, an investigational oral therapy for anemia due to chronic kidney disease in adults.
- Auryxia (ferric citrate), FDA approved for controlling serum phosphorus levels in adults with chronic kidney disease on dialysis and treating iron deficiency anemia in adults not on dialysis.
- Research and development in hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) class for various therapeutic areas.
- Clinical trials for new therapeutic agents targeting chronic kidney disease and anemia.
- Partnerships for the development and commercialization of kidney disease and anemia treatments.
- Educational and support programs for clinicians and patients dealing with chronic kidney disease and anemia.
equipe executiva do Akebia Ther
- Mr. John P. Butler MBACEO, President & Director
- Mr. Erik John Ostrowski M.B.A.Chief Business Officer, Senior VP, CFO & Treasurer
- Dr. Steven Keith Burke M.D.Senior VP and Chief Research & Development Officer
- Mr. Nicholas GrundSenior VP & Chief Commercial Officer
- Mr. Richard C. MalabreChief Accounting Officer
- Ms. Kimberly GarkoSenior VP & Chief Technical Officer
- Ms. Tracey VetterickVice President of Portfolio Strategy & Corporate Administration
- Mercedes CarrascoSenior Director of Investor & Corporate Communications
- Ms. Carolyn RucciSenior VP of Legal, General Counsel & Secretary
- Ms. Meredith BowmanSenior VP & Chief People Officer